// App-Quantinova.ai

e16503 : Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Andrew J. Armstrong

  • Celestia S. Higano

  • A. Oliver Sartor

  • Christopher Michael Pieczonka

  • Raoul S. Concepcion

  • Ronald F. Tutrone

  • Carl A. Olsson

  • James L. Bailen

  • David F. Penson

  • Nancy N. Chang

  • Jennifer Susan LIll

  • Robert Claude Tyler

  • Matthew R. Cooperberg

Medical Centers

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Duke University Medical Center, Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University, Durham, NC

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • Tulane University School of Medicine, New Orleans, LA

  • Associated Medical Professionals of NY, PLLC, Syracuse, NY

  • Urology Associates P.C., Nashville, TN

  • Chesapeake Urology Research Associates, Baltimore, MD

  • Integrated Medical Professionals, Icahn School of Medicine at Mount Sinai, New York, NY

  • First Urology Research, Louisville, KY

  • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN

  • Dendreon Pharmaceuticals, Inc., Seattle, WA

  • University of California, San Francisco, San Francisco, CA

Locations

  • United States

Companies

  • Dendreon Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Apoptotic body index

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Cabazitaxel

  • Radium-223 Dichloride

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • NCT01306890

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved